<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01041872</url>
  </required_header>
  <id_info>
    <org_study_id>2009/22</org_study_id>
    <nct_id>NCT01041872</nct_id>
  </id_info>
  <brief_title>Comparison of Different Propofol Formulations</brief_title>
  <acronym>Propofols</acronym>
  <official_title>Dose-effect of Propofol for Anesthetic Induction: Double-blind Comparison of Different Propofol Formulations Administered Alone or With Lidocaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the influence of different propofol
      formulations(plain or with lidocaine)on anesthetic induction. Propofol plain or with
      lidocaine is administered using a closed-loop algorithm in order to reach a Bispectral Index
      target of 50.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>necessary dose of propofol to obtain the induction of anesthesia (defined by a bispectral index of 50)</measure>
    <time_frame>end of anesthetic induction</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>calculated concentrations of propofol at the end of the anesthetic induction</measure>
    <time_frame>end of the anesthetic induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measured plasma propofol concentrations at the end of anesthetic induction (in 20% of patients)</measure>
    <time_frame>3 months after the end of patient's recruitment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain at injection</measure>
    <time_frame>during the PACU (post-anaesthesia care unit) stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate and arterial pressure modifications induced by anesthetic induction</measure>
    <time_frame>end of anesthetic induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients satisfaction</measure>
    <time_frame>during the PACU stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>necessary dose of propofol to obtain loss of consciousness</measure>
    <time_frame>end of anesthetic induction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>calculated concentrations of propofol at loss of consciousness</measure>
    <time_frame>end of anesthetic induction</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>General Anesthesia</condition>
  <arm_group>
    <arm_group_label>Propofol Astrazeneca</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol Astrazeneca plus lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol-lipuro B. Braun plain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol-lipuro B. Braun plus lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol Fresenius plain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol Fresenius plus lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol Astrazeneca plain</intervention_name>
    <description>Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.</description>
    <arm_group_label>Propofol Astrazeneca</arm_group_label>
    <other_name>Propofol Astrazeneca</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol Astrazeneca plus lidocaine</intervention_name>
    <description>Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.</description>
    <arm_group_label>Propofol Astrazeneca plus lidocaine</arm_group_label>
    <other_name>Propofol Astrazeneca, Lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol-lipuro B. Braun plain</intervention_name>
    <description>Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.</description>
    <arm_group_label>Propofol-lipuro B. Braun plain</arm_group_label>
    <other_name>Propofol-lipuro B. Braun</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol-lipuro B. Braun plus lidocaine</intervention_name>
    <description>Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.</description>
    <arm_group_label>Propofol-lipuro B. Braun plus lidocaine</arm_group_label>
    <other_name>Propofol-lipuro B. Braun, lidocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol Fresenius plain</intervention_name>
    <description>Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.</description>
    <arm_group_label>Propofol Fresenius plain</arm_group_label>
    <other_name>Propofol Fresenius</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol Fresenius plus lidocaine</intervention_name>
    <description>Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.</description>
    <arm_group_label>Propofol Fresenius plus lidocaine</arm_group_label>
    <other_name>Propofol Fresenius, lidocaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients scheduled for an intravenous induction of anesthesia with propofol

        Exclusion Criteria:

          -  Age under 18

          -  Pregnancy or breastfeeding

          -  Allergy to propofol, soya or peanuts,

          -  Allergy to lidocaine,

          -  History of central neurological disorder or brain injury,

          -  Patients receiving psychotropic drugs,

          -  Patient with a pacemaker.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morgan LeGuen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Foch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Saint Augustin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratoire de Pharmacologie Toxicologie, hôpital Raymond Poincaré</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Liu N, Chazot T, Genty A, Landais A, Restoux A, McGee K, Laloë PA, Trillat B, Barvais L, Fischler M. Titration of propofol for anesthetic induction and maintenance guided by the bispectral index: closed-loop versus manual control: a prospective, randomized, multicenter study. Anesthesiology. 2006 Apr;104(4):686-95.</citation>
    <PMID>16571963</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2009</study_first_submitted>
  <study_first_submitted_qc>December 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2010</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

